164 related articles for article (PubMed ID: 38459168)
1. Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cells.
van Spronsen MF; Van Gassen S; Duetz C; Westers TM; Saeys Y; van de Loosdrecht AA
Leukemia; 2024 Jun; 38(6):1365-1377. PubMed ID: 38459168
[TBL] [Abstract][Full Text] [Related]
2. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
Chesnais V; Arcangeli ML; Delette C; Rousseau A; Guermouche H; Lefevre C; Bondu S; Diop M; Cheok M; Chapuis N; Legros L; Raynaud S; Willems L; Bouscary D; Lauret E; Bernard OA; Kosmider O; Pflumio F; Fontenay M
Blood; 2017 Jan; 129(4):484-496. PubMed ID: 27856460
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotypic Profile of CD34+ Subpopulations and Their Role in the Diagnosis and Prognosis of Patients with De-Novo, Particularly Low-Grade Myelodysplastic Syndromes.
Gardikas N; Vikentiou M; Konsta E; Kontos CK; Papageorgiou SG; Spathis A; Bazani E; Bouchla A; Kapsimali V; Psarra K; Foukas P; Dimitriadis G; Pappa V
Cytometry B Clin Cytom; 2019 Jan; 96(1):73-82. PubMed ID: 30334347
[TBL] [Abstract][Full Text] [Related]
4. Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality.
Dimitriou M; Woll PS; Mortera-Blanco T; Karimi M; Wedge DC; Doolittle H; Douagi I; Papaemmanuil E; Jacobsen SE; Hellström-Lindberg E
Oncotarget; 2016 Nov; 7(45):72685-72698. PubMed ID: 27683035
[TBL] [Abstract][Full Text] [Related]
5. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.
Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M
Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050
[TBL] [Abstract][Full Text] [Related]
6. Multi-color CD34⁺ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia.
Tang G; Jorgensen LJ; Zhou Y; Hu Y; Kersh M; Garcia-Manero G; Medeiros LJ; Wang SA
Leuk Res; 2012 Aug; 36(8):974-81. PubMed ID: 22626984
[TBL] [Abstract][Full Text] [Related]
7. Establishment and validation of an updated diagnostic FCM scoring system based on pooled immunophenotyping in CD34+ blasts and its clinical significance for myelodysplastic syndromes.
Xu F; Li X; Chang CK; Guo J; Wu LY; He Q; Zhang Z; Zhu Y; Gu SC; Shi WH; Song LX; Su JY; Zhou LY; Zhang X; Wu D
PLoS One; 2014; 9(2):e88706. PubMed ID: 24558415
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117.
Haase D; Feuring-Buske M; Schäfer C; Schoch C; Troff C; Gahn B; Hiddemann W; Wörmann B
Leukemia; 1997 May; 11(5):674-9. PubMed ID: 9180291
[TBL] [Abstract][Full Text] [Related]
9. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
[TBL] [Abstract][Full Text] [Related]
10. Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry.
Kanter-Lewensohn L; Hellström-Lindberg E; Kock Y; Elmhorn-Rosenborg A; Ost A
Eur J Haematol; 1996 Mar; 56(3):124-9. PubMed ID: 8598230
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes.
Shimazaki K; Ohshima K; Suzumiya J; Kawasaki C; Kikuchi M
Br J Haematol; 2000 Sep; 110(3):584-90. PubMed ID: 10997968
[TBL] [Abstract][Full Text] [Related]
12. CD34+ cells from patients with myelodysplastic syndrome present different p21 dependent premature senescence.
Xiao Y; Wang J; Song H; Zou P; Zhou D; Liu L
Leuk Res; 2013 Mar; 37(3):333-40. PubMed ID: 23219618
[TBL] [Abstract][Full Text] [Related]
13. Increased CD34+CD38 -CD123 + cells in myelodysplastic syndrome displaying malignant features similar to those in AML.
Li LJ; Tao JL; Fu R; Wang HQ; Jiang HJ; Yue LZ; Zhang W; Liu H; Shao ZH
Int J Hematol; 2014 Jul; 100(1):60-9. PubMed ID: 24846193
[TBL] [Abstract][Full Text] [Related]
14. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.
Parker JE; Mufti GJ; Rasool F; Mijovic A; Devereux S; Pagliuca A
Blood; 2000 Dec; 96(12):3932-8. PubMed ID: 11090080
[TBL] [Abstract][Full Text] [Related]
15. The proliferation index of specific bone marrow cell compartments from myelodysplastic syndromes is associated with the diagnostic and patient outcome.
Matarraz S; Teodosio C; Fernandez C; Albors M; Jara-Acevedo M; López A; Gonzalez-Gonzalez M; Gutierrez ML; Flores-Montero J; Cerveró C; Pizarro-Perea M; Paz Garrastazul M; Caballero G; Gutierrez O; Mendez GD; González-Silva M; Laranjeira P; Orfao A
PLoS One; 2012; 7(8):e44321. PubMed ID: 22952954
[TBL] [Abstract][Full Text] [Related]
16. Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers.
Xu L; Gu ZH; Li Y; Zhang JL; Chang CK; Pan CM; Shi JY; Shen Y; Chen B; Wang YY; Jiang L; Lu J; Xu X; Tan JL; Chen Y; Wang SY; Li X; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8589-94. PubMed ID: 24850867
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo.
Knorr KL; Finn LE; Smith BD; Hess AD; Foran JM; Karp JE; Kaufmann SH
Stem Cells Transl Med; 2017 Mar; 6(3):840-850. PubMed ID: 28297583
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic application and clinical significance of FCM progress scoring system based on immunophenotyping in CD34+ blasts in myelodysplastic syndromes.
Xu F; Guo J; Wu LY; He Q; Zhang Z; Chang CK; Li X
Cytometry B Clin Cytom; 2013; 84(4):267-78. PubMed ID: 23554290
[TBL] [Abstract][Full Text] [Related]
19. Impaired generation of bone marrow CD34-derived dendritic cells with low peripheral blood subsets in patients with myelodysplastic syndrome.
Micheva I; Thanopoulou E; Michalopoulou S; Kakagianni T; Kouraklis-Symeonidis A; Symeonidis A; Zoumbos N
Br J Haematol; 2004 Sep; 126(6):806-14. PubMed ID: 15352984
[TBL] [Abstract][Full Text] [Related]
20. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
